Abolished production of interferon by leucocytes of patients with the acquired cytogenetic abnormalities 5q -- or -- 5 in secondary and de-novo acute non-lymphocytic leukaemia

British Journal of Haematology
J Pedersen-BjergaardN I Nissen

Abstract

Interferon production by leucocytes on stimulation with inactivated antigens from herpes simplex virus, varicella zoster virus and cytomegalovirus was determined in 19 patients with preleukaemia or acute non-lymphocytic leukaemia, in 15 following treatment for other tumours. Production of interferon was abolished in 10 patients and preserved in nine cases after stimulation with herpes simplex antigen. Cytogenetic studies of bone marrow demonstrated an abnormal karyotype in 13/15 patients with secondary preleukaemia or leukaemia. Characteristics were (a) hypodiploid cell lines demonstrated in eight cases, (b) a B-chromosome defect found in five cases and verified as 5q -- in four, and (c) defects in C-group chromosomes in 10, verified as monosomy 7 in nine. All four patients with de-novo preleukaemia or leukaemia had abnormal cytogenetic findings, two B-chromosome abnormalities verified as monosomy 5. A relationship between abnormalities in chromosome no. 5 and abolished production of interferon was demonstrated, as only one of seven patients with 5q --, --5 or --B produced interferon by the leucocytes, compared with eight of a total of 12 patients with other cytogenetic defects or a normal karyotype (P=0.04). The results are re...Continue Reading

References

Feb 3, 1979·Lancet·H MellstedtH Strander
Sep 1, 1978·British Journal of Haematology·M Chisholm, T Cartwright
Aug 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·L Rasmussen, T C Merigan
Jan 1, 1978·American Journal of Hematology·F RosnerM H Zarrabi
Dec 28, 1978·The New England Journal of Medicine·T C MeriganS A Rosenberg
Jul 28, 1977·The New England Journal of Medicine·R R ReimerR C Young
Dec 1, 1977·Cellular Immunology·I Gresser
Mar 1, 1977·The Journal of General Virology·Y H Tan, W Berthold
Jan 1, 1976·Acta Medica Scandinavica·H BlomgrenH Strander
Apr 1, 1975·Scandinavian Journal of Haematology·P Philip
Jul 15, 1976·International Journal of Cancer. Journal International Du Cancer·F MitelmanL Brandt

❮ Previous
Next ❯

Citations

Mar 1, 1982·Cancer Genetics and Cytogenetics·P C Nowell
Jul 1, 1984·Cancer Genetics and Cytogenetics·D C Arthur, C D Bloomfield
Oct 1, 1987·Cancer Genetics and Cytogenetics·R BergerG Flandrin
Feb 1, 1989·Cancer Genetics and Cytogenetics·M De Braekeleer, M Vekemans
Apr 30, 1981·The New England Journal of Medicine·E G Maderazo, C L Woronick
May 28, 2010·Journal of Clinical and Experimental Hematopathology : JCEH·Ryuichi AmakawaShirou Fukuhara
Nov 1, 1983·American Journal of Hematology·L P Wisniewski, K Hirschhorn
Jan 1, 1988·European Journal of Haematology. Supplementum·J Pedersen-Bjergaard, P Philip
Jul 1, 1985·Cancer Genetics and Cytogenetics·H Van den BergheG Tricot

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.